Pros and cons of existing treatment modalities in osteoporosis: a comparison between tibolone, SERMs and estrogen (±progestogen) treatments
- 1 December 2002
- journal article
- research article
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 83 (1-5) , 157-165
Abstract
No abstract availableKeywords
This publication has 70 references indexed in Scilit:
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Estrogen Receptor Isoform-Specific Induction of Progesterone Receptors in Human OsteoblastsJournal of Bone and Mineral Research, 2002
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998
- A 3-year study of prevention of postmenopausal bone loss: conjugated equine estrogens plus medroxyprogesterone acetate versus tiboloneClimacteric, 1998
- Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal WomenNew England Journal of Medicine, 1997
- The response in spinal bone mass to Tibolone treatment is related to bone turnover in elderly womenBone, 1997
- Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: A two-year randomized, placebo-controlled studyBone, 1996
- Reversal of postmenopausal vertebral bone loss by oestrogen and progestogen: a double blind placebo controlled studyBMJ, 1988
- Effects of Estrogens and Progestins on the Biochemistry and Morphology of the Postmenopausal EndometriumNew England Journal of Medicine, 1981
- Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis.BMJ, 1980